Biography
The major focus of Dr. Alizadeh’s research group is to attain a better understanding of the initiation, maintenance, and progression of lymphoid tumors, and their response to existing and novel therapies toward improving current treatment strategies. In this effort, they employ tools from functional genomics, computational biology, molecular genetics, and mouse models. They hope to apply this knowledge towards the design of clinical trials in the treatment of patients with lymphoma, leukemia, and myeloma.

Biography
Johan Skog is a renowned, well-published thought leader in exosome science having pioneered breakthrough discoveries about exosomes and other microvesicles and their vital role as cell messengers and disease proliferators. While at Massachusetts General Hospital/Harvard Medical School, Dr. Skog discovered that tumor-derived mutations can be detected in exosome RNA from serum and other biofluids, findings which were published in Nature Cell Biology in 2008. Additionally, he demonstrated that exosomes serve to deliver messages to other cells, inducing changes favorable to the proliferation of cancer. At Exosome Diagnostics, Dr. Skog continues to pioneer critical advancements in diagnostics and expand the field of exosome biology. Dr. Skog’s research background includes virology, gene therapy, brain tumors, RNA and biomarker discovery, and he is an inventor on several patents. Dr. Skog earned his Master of Biomedical Sciences and Doctorate at Umeå University, Sweden.

Clinical Dx Showcase:
Exosome Diagnostics
Exosome Diagnostics, a leader in developing liquid biopsy-based diagnostics, is the first and only company that can simultaneously isolate and analyze exosomal RNA and cfDNA in a single step to achieve highest sensitivity for detecting rare mutations. ExosomeDx empowers the world’s leading biopharma companies in exploring this unique technology.

Exosomes: New Standard In Multi-Analyte Liquid Biopsy Testing

Biography
After studying in the field of cancer epigenetics, Taylor Jensen, Ph.D. joined Sequenom in 2009 and was part of the team that developed and launched the first commercially available noninvasive prenatal test based on circulating cell-free DNA (cfDNA) in the U.S. Subsequently, Dr. Jensen has been involved in numerous assay development efforts focused on the identification and detection of genetic and epigenetic changes in cfDNA for use in prenatal and cancer diagnostics. Since the acquisition of Sequenom by LabCorp in 2016, his work has been primarily focused on precision medicine assay development and product strategy in oncology with the overarching goal of utilizing innovative technologies to improve human health.

Clinical Dx Showcase:
Labcorp
Through unparalleled diagnostics and drug development capabilities, Labcorp provides insights and accelerate innovations to improve health and improve lives.

Personalized Cancer Care-The Role of Somatic and Germline NGS Testing
Cancer is a disease of the genome with aberrations derived from both somatic and germline origins; therefore, a comprehensive genetic assessment of the tumor may be optimal to guide treatment, prognosis, and future risk for a patient and their family.

Biography
Clifford Reid is the founding CEO of Travera. Previously, Dr. Reid was the founding Chairman, President and Chief Executive Officer of Complete Genomics (NASDAQ:GNOM), a leading developer of whole human genome DNA sequencing technologies and services. Prior to Complete Genomics he founded two enterprise software companies: Eloquent (NASDAQ:ELOQ), an internet video company, and Verity (NASDAQ:VRTY), an enterprise search engine company. Dr. Reid is on the Visiting Committee of the Biological Engineering Department at the Massachusetts Institute of Technology (MIT), a member of the MIT Corporation Development Committee, and an advisor to Warburg Pincus. He earned a S.B. in Physics from MIT, an MBA from the Harvard Business School, and a Ph.D. in Management Science and Engineering from Stanford University.

Clinical Dx Showcase:
Travera
Travera has developed a new technology for identifying effective cancer drugs and drug combinations for cancer patients. We use a new measurement device invented at MIT to weigh single cells with sub-picogram accuracy, directly measuring the ex vivo response of cancer cells to cancer drugs.

A Universal Cancer Biomarker for Rapid Therapy Guidance
Travera has developed a new technology for identifying effective cancer drugs for cancer patients. We use a new measurement device invented at MIT to weigh single cells with sub-picogram accuracy, directly measuring the ex vivo response of cancer cells to cancer drugs.

Biography
Having dedicated his career to advancing innovative testing tools and treatments for conquering cancer and other debilitating diseases, Alan K. Hauser has 3 decades of experience under his belt encompassing the biotechnical, intellectual property, market, and business aspects of commercializing disruptive drug-discovery and diagnostics platforms, including pioneering microfluidic lab-on-a-chip and DNA microarray systems. With a track record of cross-functional success championing multi-omic Innovation to Commercialization (I2C) by translating promise into practice, Alan has helped launch nine genomic products and build eight bioscience businesses, with company exits exceeding $2 billion. Dr. Hauser’s prior I2C leadership directed toward companion diagnostics (CDx)-stratified precision oncology is particularly relevant as he creates value for Arvetas by charting and executing strategic ROI-led I2C roadmaps and partnering plans for the Company’s proprietary MosaicaTM multiplex spatialomics profiling (MSP) platform. The Arvetas next-generation CDx 2.0 solution holds promise to help oncologists guide treatment decisions by accurately predicting patient response.

Clinical Dx Showcase:
Arvetas Biosciences
Arvetas is a multiomic spatial profiling company developing next-generation MSP-powered companion diagnostics tests, which, unlike existing low-plex tissue biopsy-based assays, hold tremendous promise to accurately predict clinical outcomes by employing a new class of holistic signatures of a large number of mRNA and protein markers.

Predictive Diagnostics Reimagined - Multiomic Spatial Profiling
Arvetas Biosciences is championing a groundbreaking multiomic spatial profiling (MSP) platform, which, unlike other spatialomic technologies, can simultaneously interrogate a large number of biomarkers (mRNA transcripts and proteins) in clinical tissue with only one round of direct staining and imaging.

Biography
Dr. Varsha Rao is the Director of Clinical Affairs and Partnerships at ClaretBio where she oversees clinical application of the innovative NGS tools developed at ClaretBio in a variety of liquid biopsy-based diagnostic studies. Prior to her current role, Dr. Rao was a scientist at Prof. Michael Snyder’s lab at Stanford University where she lead projects that integrated cell and cell-free transcriptomic data in the context of metabolic diseases, viral infections, myelodysplastic syndrome and the NASA Twin Study. She received her Ph.D from the University of Maryland Baltimore County (2012) where she worked on identifying novel protein degradation mechanisms underlying prostate cancer progression.

Clinical Dx Showcase:
Claret Bioscience
Claret Bioscience LLC, builds NGS tools to enhance the quality of data obtained from highly degraded, low yield samples such as liquid biopsy and FFPE. Their technologies capture extremely fragmented DNA and retain native DNA termini information enabling accurate disease profiling using DNA fragmentomics.

Specialized NGS approach for improved diagnoses from highly degraded clinical samples
ClaretBio’s NGS approach SRSLY® provides the best data from the worst clinical samples. By capturing damaged, nicked, single-stranded, short fragments, and native termini from cell-free and FFPE DNA, more complex libraries and precise genomic origin are captured enabling accurate diagnoses.

Biography
Manu Tamminen is an expert in molecular biology, next- generation DNA sequencing and bioinformatics. He received his PhD from the University of Helsinki and did his post-doctoral research at MIT and ETH Zürich, where he developed methodologies for single cell sequencing and molecular counting. He is currently an Adjunct Professor and Academy Fellow at the University of Turku and has authored several high-impact research publications.

Clinical Dx Showcase:
Genomill Health
Genomill Health is a pioneering precision diagnostics company with a mission to make molecular diagnostics more scalable, sensitive and accessible for all.

Geno1 - Scalable, Sensitive and Cost-efficient Liquid Biopsies
Geno1 is a pre-sequencing platform enabling improvements in performance, cost and scalability for liquid biopsies and beyond. Geno1 combines proprietary probe design with patented NGS library preparation and AI-powered sequence processing. We present analytical validation and clinical verification of Geno1.

Biography
Clynt Taylor brings over 20 years of experience in healthcare technology innovation, both as an entrepreneur and senior executive with startup and growing companies. He joined Trapelo Health in 2017 as Chief Executive Officer and under his leadership the company developed the company’s signature product, Trapelo, which helps speed access to the most appropriate treatments for cancer patients.   Since beginning his career at IBM, he’s held leadership roles at healthcare technology companies like NextGen, where he led sales and marketing teams; HealthVision as General Manager of its fastest growing division (purchased by Lawson) and Galvanon as Co-founder and CEO Healthcare Solutions (purchased by NCR). Most recently, he held various senior executive roles with NantHealth – including leading the innovation, launch and commercialization of eviti, Inc., recognized today as one of the nation’s premier oncology decision support solutions.

Clinical Dx Showcase:
Trapelo Health
Trapelo Health is a health technology company on a mission to address the challenges that result from rapid changes in the science, technology and business of next-generation cancer care. Its product, Trapelo, is a win-win solution for doctors, labs and payers that need real-time, evidence-based information and full transparency to make patient-based decisions faster. As part of this commitment, Trapelo founded The Precision Medicine Podcast.

Precision Oncology Platform Accelerates Biomarker Adoption
See the decision-support platform that accelerates biomarker adoption and patient access to targeted therapies overnight.

Biography
Dr. Haita Makanji joined Magellan Rx Management in 2014. She is the vice president of clinical strategy and innovation within specialty in which she assumes several roles and responsibilities, including development and management of specialty clinical programs and interfacing with payers and pharmaceutical companies to bring industry-leading solutions that curb rising specialty spend. She is responsible for design, implementation, and operations of specialty clinical programs that improve the quality of care for patients with high-cost disease states across several lines of business including employer groups and Medicaid plans. She oversees the Comprehensive Oncology Management Program which encompasses innovative utilization management strategies with complex case management. Additionally, Dr. Makanji leads a team of pharmacists, including board-certified oncology pharmacists who are tasked to support payers and assist with comprehensive medical and pharmacy data analyses, prior authorization and medical policy design, and organizing unique key opinion leader thought leadership panels.

Clinical Dx Showcase:
Magellan Rx Management
Magellan Rx Management, a division of Magellan Health, Inc., is shaping the future of pharmacy. As a next-generation pharmacy organization, we deliver meaningful solutions to the people we serve. As pioneers in specialty drug management, industry leaders in Medicaid pharmacy programs and disruptors in pharmacy benefit management, we partner with our customers and members to deliver a best-in-class healthcare experience.

Collaborative Precision Medicine Platform Accelerates Biomarker Adoption
The lag in biomarker adoption is preventing patients from accessing life-extending precision therapies and trials. Learn about the only collaborative, decision-support platform that aligns oncologists, labs and payers, streamlines ordering and ensures the right biomarkers are tested every time.

Biography
An executive with more that 20 years of leadership experience in creating revenue-generating business lines, management, scaling operations, business strategy, marketing, joint ventures and partnerships. Kamal is the President of Invitae Digital Health, which empowers healthcare executives and providers with actionable information for taking on some of the most difficult problems—from cancer to cardiovascular disease, reproductive health to medication optimization.

Digital Health Showcase:
Invitae
Our genes can transform our health. Invitae's mission is to bring genetics to mainstream medicine to improve healthcare for billions.

Clinical Decision Support Tools in Oncology
Digital Health Platform can keep providers informed, promote shared-decision making, and in turn empower the patient.

Biography
At BillionToOne, David co-developed the molecular counter platform that increases the resolution of cell-free DNA diagnostics by over a thousand-fold. This technology was used to develop BillionToOne’s single-gene NIPT, which is the only (and fastest-growing) test that can detect the most common inherited disorders such as sickle cell disease, cystic fibrosis, and spinal muscular atrophy in the fetus directly from maternal blood. David is the co-founder and CTO at BillionToOne. He was the lead author of BillionToOne's foundational patents and single-gene NIPT clinical trial, which was published in Nature Scientific Reports. His work has been supported by the NHLBI of the National Institutes of Health. Previously, David received his PhD in Bioengineering from Rice University. He graduated cum laude from Princeton University with a Bachelor’s in Physics and minors in Biophysics and Engineering & Management Systems.

Clinical Dx Showcase:
BillionToOne Inc.
BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more powerful, accurate, and accessible for all. Our QCT molecular counting platform enables us to offer unique products from single-gene NIPT to quantitative liquid biopsy for treatment monitoring.

Molecular Counting Enables High-resolution Liquid Biopsy Assay
We describe a novel pan-cancer treatment monitoring liquid biopsy assay that quantifies the changes in cell-free tumor DNA levels at single-molecule resolution, without the need for tissue.

Biography
Dr. Asaf Zviran brings 15+ years of R&D management in biology and defense.To date he has managed to publish 13 papers with over 1,700 citations (including Nature and Stem Cell). Asaf received multiple awards and grants. He is an IDF R&D Officer (Captain) with a PhD in Molecular Biology.

Clinical Dx Showcase:
C2i Genomics
C2i Genomics is the first company to develop post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA.

C2i’s Cancer Recognition for Personalized Treatment Monitoring
C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging low-input blood (only 2mL blood) whole-genome sequencing to provide high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development.

Biography
Dr. Ying Huang has over 25 years of research and industry experience with a broad knowledge in technology and assay development. Ying is passionate about developing novel methods using innovative technologies to improve lives with precision diagnostics. Her current work is focused on assays for diagnosis, stratification and risk-directed treatment strategies in hematologic disease. Prior to Invivoscribe, she worked at Illumina, Acea Biosciences, Nanogen and MD Anderson Cancer Center. In those roles, she developed a variety of methods ranging from isolating CTC using microfluidic devices, to detecting biowarfare agents using electronic microarray. She is co-author of more than 60 publications and abstracts and is co-inventor on 9 patents. Ying received her Ph.D in Electrical Engineering from Bangor University, UK.

Clinical Dx Showcase:
Invivoscribe
Invivoscribe is a global leader in hemato-oncology diagnostics. Our flow & molecular assays, reagents, controls, bioinformatics & services focus on actionable biomarkers supporting therapeutic decisions, MRD testing, stratification & CDx development.

A Comprehensive Solution for AML Precision Diagnostics
AML is an aggressive, highly heterogeneous disease. Invivoscribe offers a comprehensive solution for AML precision diagnostics, risk stratification, prognosis and treatment strategies using complementary molecular and flow assays to optimize patient care and accelerate drug approvals worldwide.

Biography
Dr. Chabon is a co-founder of Foresight Diagnostics where he is focused on commercializing a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that enables detection of ctDNA at levels as low as one part-per-million. He is a molecular biologist and bioinformatic scientist by training with extensive NGS assay development experience. He has authored more than 20 peer-reviewed publications and has 3,000+ citations to date (including papers published in Nature and Nature Biotechnology describing Foresight’s liquid biopsy platform). Prior to founding Foresight, Dr. Chabon’s research focused on using cancer genomics to inform better personalized treatment strategies for patients. He completed his Ph.D and postdoctoral training at Stanford University under the co-mentorship of Dr. Max Diehn and Dr. Ash Alizadeh with whom he co-founded Foresight Diagnostics in 2020.

Clinical Dx Showcase:
Foresight Diagnostics
Foresight Diagnostics is developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD). The improved sensitivity of the Foresight MRD assay can provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches.

Foresight’s Ultra-Sensitive Liquid Biopsy Improves MRD
Foresight’s ultra-sensitive liquid biopsy platform improves MRD detection rates in patients with B-cell lymphomas and solid tumors by tracking a unique class of somatic mutation, termed ‘phased variants’, that enables detection of ctDNA at levels as low as one part-per-million.

Biography
Mohamad Sater is the Director of Computational Biology at Day Zero Diagnostics, a healthcare startup spun out of Harvard University to develop a genomic sequencing-based rapid diagnostic for bacterial infections. Dr. Sater received his PhD in Microbiology from the Swiss Institute of Bioinformatics and Basel University, then completed a postdoctoral fellowship at Harvard University. His academic research focused on bacterial mechanisms of antibiotic resistance and persistence. He also developed data analysis methods leveraging whole genome sequencing data and clinical metadata to investigate microbial transmission dynamics and reconstruct outbreaks.

Microbial Profiling Showcase:
Day Zero Diagnostics
Day Zero Diagnostics is an infectious disease diagnostics company using whole-genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.

Definitive Clonality Determination in Hospital-acquired Infection
epiXact: a rapid WGS service that provides hospitals with definitive answers for infection transmission investigations.

Biography
Klaus Lindpaintner, MD, MPH, FACP, Chief Scientific and Medical Officer at InterVenn Biosciences, previously held senior positions at Pfizer as Sr. VP and Global Head, Human Genetics and Computational Biomedicine, at Hoffman-La Roche, as Distinguished Scientist and Global Head, Roche Center for Medical Genomics, spearheading the company’s efforts in personalized health care; as CSO at Thermo-Fisher-Scientific; and on the faculty of Harvard Medical School. Klaus has co-authored some 250 scientific papers, and holds honorary and adjunct professorships at several academic institutions. He serves on numerous boards, working groups, and advisory panels for trade organizations, regulatory authorities, and non-governmental organizations on issues related to the successful implementation and leverage of novel technologies in health care. Klaus graduated from Innsbruck University Medical School with a degree in medicine, and from Harvard University with a degree in public health. He pursued post-graduate training and specialization in internal medicine, cardiology, and clinical and molecular genetics in the US and Germany and is a Diplomate of the Boards in these specialties.

Clinical Dx Showcase:
InterVenn BioScience
InterVenn has developed a unique technology platform that combines high resolution mass spectrometry with high throughput artificial-intelligence powered data processing, allowing interrogation of the human glycoproteome at clinical study scale.

Glycoproteomic Profiling: Powerful Predictor of Immunotherapy Response
Using InterVenn's platform we have been able to demonstrate that serum glycoprotein profiles are powerful predictors of likely response or non-response to checkpoint inhibitors, clearly superior to currently available biomarkers across a range of indications and drug molecules.

Biography
Dr. Ge’s work focuses on the innovations in the public health and life science sector. Prior to Apostle, he was Director of Bioinformatics at Gilead Sciences between 2011 and 2016. Between 2008 and 2011, he was Assistant Professor at Duke University School of Medicine, where he was also a member of U.S. NIH NHGRI Special Emphasis Panel. He and colleagues discovered the IL28B genetic variants associated with clinical response to anti-HCV treatment, published in Nature in 2009.

Clinical Dx Showcase:
Apostle Diagnostics
Apostle Inc is a biotechnology company in San Jose, CA. Apostle responds to the COVID-19 pandemic with a Viral RNA Isolation System that has processed over 12 million clinical samples, as well as a CLIA lab helping international travelers.

Apostle COVID-19 RNA Extraction System
This presentation illustrates the effective detection of SARS-CoV-2 using the Apostle COVID-19 Viral RNA Isolation Automation System and qRT-PCR from over 12 million samples in clinical lab settings. A CLIA lab helping international travelers is also discussed.

Biography
Gerald Commissiong is President & CEO Todos Medical Ltd. (OTCQB: TOMDF), in addition to Amarantus Bioscience Holdings, Inc. and interim-CEO of Breakthrough Diagnostics, Inc., Todos’ joint venture with Amarantus. Mr. Commissiong has been responsible for Amarantus’ strategic transactions, licensing, research collaborations, mergers & acquisitions in therapeutics and diagnostics, as well as fund raising, having raised over of $50 million since inception. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University.

Clinical Dx Showcase:
Todos Medical
Todos Medical is a commercial in vitro diagnostics company focused on developing novel, convenient tests for the early detection of COVID-19, cancer and neurodegenerative disorders.

Tollovir: Phase II Covid-19 Antiviral Drug Candidate
Tollovir: Phase II, Antiviral 3CL-Protease Inhibitor for Hospitalized Covid-19 Patients

Biography
Genetika+ is focused on personalizing treatment in the mental health space, with a first product focusing on optimizing drug choice in depression. Prior to co-founding Genetika+ , Daphna was Chief Scientific Officer at Ibex Medical Analytics, a digital health company developing AI-based cancer diagnostics, and before that, she served as Head, Personalized Medicine and Diagnostics at Teva Pharmaceuticals, where she supported the discovery, development and differentiation of Teva’s pipeline drugs, in collaboration with the Israeli healthcare sector and multinational companies. Daphna joined Teva after having led biomarker and diagnostic development activities within the pipeline of multiple top-10 pharma and fortune 500 companies. She served in several roles with increasing responsibility at Selventa, a system's biology company focused on personalized medicine, and founded the Israeli branch of the company, as Global Head of Diagnostics. Daphna trained as post-doc at Harvard University, after receiving her PhD in Medical Sciences from the Technion.

Clinical Dx Showcase:
Genetika+
Genetika+ personalizes treatment in the mental health space, initially focusing on depression. The Genetika+ platform uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Brain in a Dish: Personalizing Treatment in Depression
Major depression is a leading cause of health-related burden globally, further exacerbated by Covid-19. Despite the availability of many antidepressant on the market, most patients do not effectively respond to the prescribed treatment. Genetika+’s RxMine platform converts patients' blood cells into neurons, which in turn are used to screen for the optimal drug for each individual. By combining the patient’s genetics and medical history into an AI-based algorithm, a tailored report describes the optimal drug for each patient.

Biography
Jhana Hendrickx holds a Master degree in bioscience and cell gene Biotechnology, and a PhD in Biomedical sciences. Jhana joined Novosanis, a medical device company in Antwerp, Belgium in 2021. Shes in charge of scientific affairs, managing the Key Opinion Leader Network, running Scientific Advisory Boards and engaging with our customers. Also, shes in charge of clinical affairs and runs the in-house clinical trials in infectious diseases and oncology and supports trials executed by lead Principal Investigators globally.

Clinical Dx Showcase:
Novosanis
Novosanis is a wholly owned subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology.

Urine as a non-invasive liquid biopsy for oncology applications
A high number of potentially informative cancer biomarkers have been found in urine.

Biography
Marija Plodinec co-founded ARTIDIS AG and in November 2017 became the CEO and a Member of the Board of Directors. She studied physics in Zagreb and received her doctorate in 2010 from the University of Basel. For twelve years, she has driven the development of ARTIDIS, a medical device for fast and early diagnosis of breast cancer based on a unique nanomechanical biomarker, bringing the technology from basic research to the first clinical studies. Marija Plodinec is a recognized expert in the field of physical sciences in oncology and has co-authored important scientific papers and patents in this field. She is also a member of several international organizations focusing on cancer research and its clinical applications. Under her leadership, ARTIDIS fundraised more than 25M USD, successfully completed the large clinical study on 545 patients in Switzerland, grew to +40 FTE and partnered up with leading US pharmaceutical and clinical institutions.

Clinical Dx Showcase:
Artidis AG
ARTIDIS AG is a clinical stage medical technology company developing the first nanotechnology platform for tissue analysis combined with a digital data platform intended for broad use in drug discovery, tissue engineering as well as for rapid diagnostics and personalized treatment optimization.

ARTIDIS: Changing the Paradigm of Tissue Analysis
ARTIDIS: Changing the paradigm of tissue analysis with a novel nanotechnology platform that delivers personalized patient treatment strategies and accelerates drug development.

Biography
Ron is a 35+ year veteran of the Diagnostics and Molecular Diagnostics markets and is currently the CEO of Oncocyte. He was an early pioneer in the development and commercialization of molecular panels in Oncology. He is an ardent ambassador for decentralization of molecular testing to ensure access to this life saving information to all patients in all communities.

Clinical Dx showcase:
Oncocyte
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.

Driving a Paradigm Shift for Patient Management
As cancer continues to move from a deadly disorder to a manageable chronic disease, a new paradigm for molecular diagnostics is emerging to better serve patient and physicians. Combining precision therapy selection tests with blood based monitoring enables better outcomes.

Biography
Thuy Phung, MD, PhD is associate professor and medical director of molecular pathology & dermatopathology at the University of South Alabama. She has been spearheading efforts to enhance molecular diagnostics for cancer patients in underserved areas in the Gulf Coast region by establishing rapid single-gene testing as well as actionable, cost-effective next generation sequencing (NGS) assays. She is the lead author of Pediatric Dermatopathology, a comprehensive textbook in the field. Dr. Phung is passionate about global health. She co-founded the award-winning Vascular Anomalies Center in Ho Chi Minh City, Vietnam, which cares for thousands of underserved children with vascular birthmarks, and is leading efforts to establish molecular diagnostics for these disorders.

Clinical Dx Showcase:
University of South Alabama
University of South Alabama is an academic healthcare system comprised of university hospital, women & children's hospital, cancer institute and affiliated medical clinics that provide quality healthcare services to communities across the Gulf Coast region.

Establishing Molecular Testing in Communities
Molecular diagnostics provide important genetic information for informed precision cancer care. However, molecular testing, such as broad-panel testing, remains underutilized in oncology practices in community/small laboratory setting. The presentation’s aim is to explore and address the gap in molecular testing in underserved communities.

Biography
Pat Arensdorf is co-founder and Chief Executive Officer of Exai Bio, a next-generation liquid biopsy company using cell-free RNA to enable the earlier and more accurate diagnosis of cancer. Previous to Exai Bio, he has been involved in the founding, strategy and executive management of several companies, including Bluestor Genomics, Critical Diagnostics, Diadexus (acquired by Diazyme), Immumetrix (acquired by CareDx), Tethys Bioscience (acquired by HDL), Intersect ENT (IPO), and First Medical (acquired by Sigma-Aldrich). Pat began his career in finance and strategic consulting in private equity. He received his bachelor's degree in Molecular Biology from Princeton and his masters from the Stanford GSB.

Clinical Dx Showcase:
Exai Bio Inc.
Exai Bio is a next-generation liquid biopsy company. The company's propriety RNA and AI-based liquid biopsy platform delivers clinical insights into cancer biology. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, and treated in a personalized way.

OncRNA: a Novel Liquid Biopsy Technology Platform
Orphan non-coding RNAs (oncRNAs) are a novel and previously unannotated class of small non-coding RNAs, and are observed in many types of cancer but not seen in normal tissue. OncRNAs enable a next-generation RNA-based liquid biopsy strategy for detecting cancer.

Biography
Dr. Milburn received his Ph.D. in Biophysical Chemistry at the University of California, Berkeley and was a research fellow at Harvard Medical School for his post-doctoral work. Dr. Milburn has over 25 years of experience in biotech and pharmaceutical companies including over 20 years in senior management research positions. Dr. Milburn has published over 100 scientific articles on technology, research and development in the life sciences. At GeneCentric, Dr. Milburn is responsible for the RNA-based diagnostics development and commercialization.

Clinical Dx Showcase:
GeneCentric Therapeutics
GeneCentric develops and commercialize next generation oncology diagnostics and companion diagnostics built on RNA gene expression signatures in partnership with Biopharma companies and commercial reference labs.

Novel Oncology RNA-based Companion Diagnostics Development
RNA-based complementary and companion diagnostics could identify more patients able to receive clinical benefit from cancer therapeutics and increase response rates. RNA diagnostics better reflect the inherent expressed traits of a tumor, including genetic drivers and the immune environment.

Biography
Ryan Dittamore has developed and commercialized multiple oncology products utilized in medicine today. Most recently, he was CBO of Decipher Biosciences, and previously Chief of Medical Innovation at Epic Sciences, where he led the clinical development, reimbursement, guideline support, and commercial partnering of the AR-V7 test (the first predictive test in prostate cancer). Ryan has also held roles at Roche Dx (Ventana), Genisphere (Code Biotherapeutics), and Bio-Rad. Cumulatively, he has partnered with over 60 biopharma companies, is the author of over 30 peer-reviewed publications, and inventor of 12 patents issued and pending.

Clinical Dx Showcase:
Cordance Medical
Cordance Medical is enabling precision medicine for brain tumors. We are developing a device that opens the Blood-Brain Barrier in a temporary, non-invasive, and patient-friendly manner enabling liquid biopsies and improved drug delivery.

Non-invasive BBB Penetrance to Enable Precision Medicine
An overview of our non-invasive, globally scalable Blood-Brain Barrier (BBB) penetrance device to enable liquid biopsies for patients with primary brain tumors and brain metastasis to receive a contemporary liquid biopsy and improved drug delivery.

Biography
Dr. Grosu founded PetDx in 2019 after his beloved dog Poppy succumbed to pancreatic cancer at the age of 4, less than two months after her diagnosis. The ordeal motivated him to assemble a team of experts in genomics and veterinary medicine around a simple goal: using the latest advances in genome sequencing to revolutionize the early detection of cancer in pets. Most recently, Grosu, who studied medicine at Saint Louis University School of Medicine and earned an MBA from the University of Oxford, served as chief medical officer at Sequenom. Previously, he had been the first chief medical officer of Illumina, where he established the clinical development and medical affairs operations, and led the clinical studies underlying regulatory clearance of the world’s first next-generation sequencing IVD platform and assay.

Clinical Dx Showcase:
PetDx
PetDx® – The Liquid Biopsy Company for Pets™ is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The company's flagship product, OncoK9®, enables veterinarians to detect cancer in dogs with a simple blood draw.

Veterinary Liquid Biopsy: The Next Frontier in Clinical Genomics
The high degree of homology between human and canine malignancies, and the high prevalence of certain cancers in dogs that are rare in humans, offer unique opportunities for large-scale, fast-tracked comparative oncology studies using widely available liquid biopsy testing methods.

Biography
Lauren recently entered the Digital & Advanced Analytics market as a new business development representative for Collaborative Drug Discovery (CDD). In her first 3 years she has focused on helping organizations implement state of the art digital workflows through the implementation of cloud-based research data storage and analytics solutions. As a CDD Vault Account Manager, Lauren helps R&D organizations better understand how they can store, analyze and share their research results.

Clinical & Research Tools Showcase:
Collaborative Drug Discovery
CDD advances science through better data management. It’s CDD Vault® product, is a hosted informatics solution that allows researchers to organize data and experiments and securely collaborate in real time. CDD also offers BioHarmony™ Drug Data Store and Annotator an ML assisted bioassay annotation platform.

Challenges of storing R&D data for novel biologics
New CDD Vault features for efficient storage and analysis of R&D result data for biological entities.

Biography
Dr Pahini Pandya is the CEO and co-founder of Panakeia Technologies, which enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images, using AI and without the need for any lab assays. Trained as a cancer researcher Dr. Pahini Pandya spent the last decade furthering translational research in the field. She pursued a PhD in cancer biophysics at King’s College London, a postdoc at the University of Cambridge and has several publications in top journals. Educated at the Stanford and Cambridge business schools, Pahini has also held several leadership positions across entrepreneurial organisations and helped numerous start-ups commercialise research. She has been recognised as Global Shaper by the World Economic Forum, and received multiple awards for entrepreneurship.

Clinical Dx Showcase:
Panakeia
Panakeia enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images, using AI and without the need for any lab assays.

TBC
Overview of Panakeia's approach for digital biomarker profiling of cancer tissues and applicability for research and clinic.